What Are Commodities? – The Motley Fool
What Is a Conservatorship?
What Does Cash-on-Cash Return Mean?
What Is a Correlation Coefficient?
What Is a Confidence Interval?
What Is a Chief Technology Officer (CTO)?
What Is Cost Per Thousand (CPM)?
» Read more about: What Are Commodities? – The Motley Fool »
Read MoreSoon, you can invest in mutual funds via post offices
10:02 am
What’s the story
The Department of Posts (DoP) has partnered with the Association of Mutual Funds in India (AMFI) to distribute mutual funds through post offices.
» Read more about: Soon, you can invest in mutual funds via post offices »
Read MoreCentral bankers fear being caught in Federal Reserve's storm
JACKSON HOLE, WYOMING –
Central bankers gathered at a U.S. mountain resort over the weekend are starting to fear that the political storm surrounding the U.S. Federal Reserve may engulf them too.
U.S. President Donald Trump’s efforts to reshape the Fed to his liking and pressure it into interest rate cuts have raised questions about whether the U.S.
» Read more about: Central bankers fear being caught in Federal Reserve's storm »
Read MoreTrade war deepens decline for China’s powerhouse province
During the heyday of Chinese low-cost manufacturing, the town of Houjie was renowned for its shoemakers and the raucous nightlife laid on for the thousands of foreign and domestic buyers who visited each year.
Like other parts of Guangdong, it boomed after China became the world’s export powerhouse and the southern province became a test bed for capitalism and foreign investment as the home of the country’s first special economic zones.
» Read more about: Trade war deepens decline for China’s powerhouse province »
Read MorePalantir Slipped Today — Is the Artificial Intelligence (AI) Stock a Buy Right Now?
Key Points
-
Palantir stock lost a small amount of ground amid pullbacks for the S&P 500 and Nasdaq Composite.
The Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Breaking the $1 Billion Barrier, What’s Next for Security Leader?
CyberArk Software (NASDAQ: CYBR) just delivered a standout quarter, officially surpassing $1 billion in annual revenue for the first time in fiscal 2024. The identity security powerhouse—best known for its privileged access management solutions—is scaling at an impressive pace, fueled by surging demand, strategic acquisitions, and a seamless transition to a subscription-based model.
We take a deep dive into CyberArk’s latest earnings,
» Read more about: Breaking the $1 Billion Barrier, What’s Next for Security Leader? »
Read MoreThe Spotlight
Stagflation Is Here to Stay, How To Invest?
Back in the 1970s when stagflation took hold the world looked a whole different than it does today. Landlines have been replaced by mobile phones. TVs have been replaced by streaming apps. Records have been replaced by Spotify. But one thing that hasn’t changed is the definition of stagflation, a period where inflation rises at a more rapid pace than the economy.
» Read more about: Stagflation Is Here to Stay, How To Invest? »